The pricing of Aduhelm has been compared to that of Sovaldi, but this ignores the fact that Sovaldi actually worked.
A fiercely competitive three-horse race in spinal muscular atrophy is Evrysdi’s for the taking.
The new price for its Covid-19 vaccine is lower than earlier deals – but arguably not by much.
By signalling that its Covid-19 vaccine could cost just a few dollars Astra could seriously embarrass its competition.
Companies and investors have not completely dismissed the UK Labour party’s proposals for cheaper drugs – but some ideas have proven more equal than others.
Novo Nordisk says that oral semaglutide’s list price will be “similar” to Ozempic’s, but it will be a while before its true cost becomes apparent.
Roche’s lower price tag for its targeted cancer therapy Rozlytrek could – intentionally or not – hit one of Bayer’s big hopes hard.
Pfizer opts not to start a price war with Alnylam and Ionis, but could there be a pricing loophole?
An Icer report questioning the cost effectiveness of Aimmune and DBV's peanut allergy projects is yet another reason to be cautious about the companies'…